Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EFFICACY OF TERIPARATIDE ON THE RISK OF VERTEBRAL FRACTURE AND THE INTERACTION WITH FRAX

Trial Profile

EFFICACY OF TERIPARATIDE ON THE RISK OF VERTEBRAL FRACTURE AND THE INTERACTION WITH FRAX

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Apr 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teriparatide (Primary)
  • Indications Osteoporosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Asahi Kasei
  • Most Recent Events

    • 29 Apr 2014 New trial record
    • 02 Apr 2014 Results presented at the 2014 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top